Japan colorectal tumor prevention study: randomized controlled trial of curcumi
- Conditions
- colorectal tumor
- Registration Number
- JPRN-UMIN000018817
- Lead Sponsor
- Management Committee
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 600
Not provided
# Patients with a medical history of submucosal or deeper colorectal cancer. # Patients currently taking antithrombotics such as Bayaspirin, Bufferin, Panaldine, Warfarin, Persantin and NOAC. # Patients who have undergone colorectal resection (those who have undergone appendectomy are allowed to participate in the study). # Patients with familial colorectal adenoma. # Patients with any existing cancer at the time of participation in the study. # Patients with known allergy to curcumin. # Patients currently taking anticancer drugs. # Women who are or may be pregnant during the study period. # Patients currently taking NSAIDs at least 3 times weekly, for example, as a analgesic. # Patients with ulcerative colitis or Crohn's disease # Patients with bleeding tendency or platelet count less than 70,000. # Patient taking turmeric as a supplement. # Patient deemed inappropriate by a doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The occurrence of a colorectal tumor (adenoma or cancer) is selected as the primary endpoint.
- Secondary Outcome Measures
Name Time Method